报价延迟最少15分钟:2026/08/26 00:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.7 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.49/0.75
|
|
企业价值
6.43B
|
| 资产负债 |
|
每股账面净值
6.62
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
1.19B
|
|
每股收益
4.10
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America. |
